Health Tip: Managing Hair Loss From Chemotherapy

Source: Cancercompass News: Other Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

Purpose: Permanent chemotherapy-induced alopecia (pCIA) is an increasingly recognised complication of taxane-based chemotherapy that may be associated with significant psychological morbidity [1]. The prevalence of pCIA following docetaxel is poorly understood and there are no published data on paclitaxel chemotherapy. Here we analyse prevalence and patterns of pCIA in patients who received docetaxel or paclitaxel across two UK tertiary cancer centres.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
             Basel, 29 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Phesgo ™, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection in combination with intravenous (IV) chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer. This is the first time that Roche has combined two monoclonal antibodies that can be administered by a single SC i...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Chemotherapy-induced alopecia is psychologically challenging for patients undergoing cancer treatment, and scalp cooling has been shown to prevent or decrease the hair loss.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Source Type: research
ConclusionsSleep disturbances have lately emerged as the most severe problem in women with OC or BC receiving anticancer therapy. Concerns about family and partner were ranked second in the current study and first in previous investigations.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
ConclusionsThis study indicates that carboplatin plus taxanes could be a feasible adjuvant chemotherapy for patients with early TNBC who are cannot tolerate intensive chemotherapy with anthracycline.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
ConclusionsThis study indicated that CT ‐707 is clinically effective as a new antitumor drug for Chinese lung adenocarcinoma patients with ALK rearrangement. It is safe and reliable and the dose‐expansion phase recruitment has started.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Basel, 25 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for the fixed-dose combination (FDC) of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subc utaneous (SC) injection in combination with intravenous (IV) chemotherapy, for the treatment of eligible patients with HER2-positive breast cancer. The BLA for the FDC is based on results from the phase III FeDeriCa study, which demonstrated non-inferior levels of Perjeta in the blood (phar...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
This study aimed to evaluate the impact of a topical lotion (CG428) on hair thickness and density in breast cancer survivors with permanent chemotherapy-induced alopecia (PCIA).MethodsThe study was a double-blind, randomized controlled trial which conducted from February 2016 to December 2016 at the Samsung Comprehensive Cancer Center in Seoul, South Korea. Breast cancer patients with PCIA were randomized on average of 3.5  years after chemotherapy. Topical lotion (Batch DT023) is a botanical drug under development containing a novel patented blend of 4 botanical ingredients: citrus, cocoa, guarana, and onion. Partici...
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet ...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
Publication date: Available online 1 February 2020Source: Clinica Chimica ActaAuthor(s): Neera Yadav, Shama Parveen, Monisha BanerjeeAbstractCervical cancer is common among women with a recurrence rate of 35% despite surgery, radiation, and chemotherapy. Patients receiving chemotherapy or radiotherapy routinely experience several side effects including toxicity, non-targeted damage of tissues, hair loss, neurotoxicity, multidrug resistance (MDR), nausea, anemia and neutropenia. Phytochemicals can interfere with almost every stage of carcinogenesis to prevent cancer development. Many natural compounds are known to activate/...
Source: Clinica Chimica Acta - Category: Laboratory Medicine Source Type: research
More News: Alopecia | Cancer | Cancer & Oncology | Chemotherapy